Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973761 | 0.98 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL14172747 | 0.91 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL14172625 | 0.88 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL14172714 | 0.87 | HPGD (0.42) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL14172725 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL14172732 | 0.87 | NPC1 (0.42) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL14172631 | 0.84 | NPC1 (0.42) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL14172724 | 0.84 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL14172616 | 0.84 | SMN1; SMN2 (0.60) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL4973227 | 0.83 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384947-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| US-7144885-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | BAYER HEALTHCARE LLC | 2005-07-28 | — | — | US | disclosed |
| EP-1478639-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003072566-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | MKI67, CCNA2, CDK4 | KDM4E 3497/4885ALDH1A1 973/4885HPGD 189/4885 |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | MKI67, CCNI, PCNA | KDM4E 3721/4885ALDH1A1 637/4885HPGD 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.